The Role and Implications of COVID-19 in Incident and Prevalent Heart Failure

Juan Simon Rico-Mesa1, Justin Haloot2, B K Anupama2

  • 1Department of Cardiology, Johns Hopkins Medicine, Baltimore, MD, USA.

PubMed

Insights

COVID-19 significantly worsens heart failure outcomes, increasing severity and mortality through mechanisms like cytokine storms and thrombosis. Survivors face long-term cardiovascular risks, necessitating further research for better management.

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Pathophysiology

Background:

  • COVID-19 poses significant risks to cardiovascular health.
  • Pre-existing heart failure complicates COVID-19 prognosis.

Purpose of the Study:

  • To review the pathophysiological interactions between COVID-19 and heart failure.
  • To elucidate mechanisms driving worse outcomes in COVID-19 patients with heart failure.

Main Methods:

  • Literature review of pathophysiological interactions.
  • Analysis of mechanisms exacerbating heart failure during COVID-19.

Main Results:

  • Heart failure patients experience severe COVID-19 symptoms and higher mortality.
  • Mechanisms include cytokine storms, myocardial infarction, myocarditis, and thrombosis.
  • Elevated cardiac biomarkers (troponin, natriuretic peptides) indicate severe disease.
  • Long-term risks for survivors include new heart failure, cardiomyopathy, and cardiac arrest.

Conclusions:

  • COVID-19 severely impacts patients with pre-existing heart failure.
  • Ongoing research is crucial for targeted therapies and improved management.
  • Better prevention, diagnosis, and treatment strategies are needed for heart failure in the context of COVID-19.
Abstract

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
333
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
414
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
559
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
356